Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review.
Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review.
复制标题
DOI:
10.1186/s40001-021-00524-8
复制
发表时间:
2021-06-08
影响因子:
4.2
通讯作者:
Shayesteh Jahanfar
中科院分区:
文献类型:
--
作者:
SeyedAlinaghi S;Mirzapour P;Dadras O;Pashaei Z;Karimi A;MohsseniPour M;Soleymanzadeh M;Barzegary A;Afsahi AM;Vahedi F;Shamsabadi A;Behnezhad F;Saeidi S;Mehraeen E;Shayesteh Jahanfar
Coronavirus Disease-2019 (SARS-CoV-2) started its devastating trajectory into a global pandemic in Wuhan, China, in December 2019. Ever since, several variants of SARS-CoV-2 have been identified. In the present review, we aimed to characterize the different variants of SARS-CoV-2 and explore the related morbidity and mortality. A systematic review including the current evidence related to different variants of SARS-CoV-2 and the related morbidity and mortality was conducted through a systematic search utilizing the keywords in the online databases including Scopus, PubMed, Web of Science, and Science Direct; we retrieved all related papers and reports published in English from December 2019 to September 2020. A review of identified articles has shown three main genomic variants, including type A, type B, and type C. we also identified three clades including S, V, and G. Studies have demonstrated that the C14408T and A23403G alterations in the Nsp12 and S proteins are the most prominent alterations in the world, leading to life-threatening mutations.The spike D614G amino acid change has become the most common variant since December 2019. From missense mutations found from Gujarat SARS-CoV-2 genomes, C28854T, deleterious mutation in the nucleocapsid (N) gene was significantly associated with patients' mortality. The other significant deleterious variant (G25563T) is found in patients located in Orf3a and has a potential role in viral pathogenesis. Overall, researchers identified several SARS-CoV-2 variants changing clinical manifestations and increasing the transmissibility, morbidity, and mortality of COVID-19. This should be considered in current practice and interventions to combat the pandemic and prevent related morbidity and mortality.
登录
查看更多内容
影响因子:
4.9
作者:
Forni D;Cagliani R;Pontremoli C;Mozzi A;Pozzoli U;Clerici M;Sironi M
通讯作者:
Sironi M
影响因子:
168.9
作者:
Chan, Jasper Fuk-Woo;Yuan, Shuofeng;Yuen, Kwok-Yung
通讯作者:
Yuen, Kwok-Yung
影响因子:
3.7
作者:
De Vito A;Fiore V;Princic E;Geremia N;Panu Napodano CM;Muredda AA;Maida I;Madeddu G;Babudieri S
通讯作者:
Babudieri S
影响因子:
64.8
作者:
Gordon, David E.;Jang, Gwendolyn M.;Krogan, Nevan J.
通讯作者:
Krogan, Nevan J.
DOI:
10.1126/science.abh2644
发表时间:
2021-05-21
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Faria NR;Mellan TA;Whittaker C;Claro IM;Candido DDS;Mishra S;Crispim MAE;Sales FCS;Hawryluk I;McCrone JT;Hulswit RJG;Franco LAM;Ramundo MS;de Jesus JG;Andrade PS;Coletti TM;Ferreira GM;Silva CAM;Manuli ER;Pereira RHM;Peixoto PS;Kraemer MUG;Gaburo N Jr;Camilo CDC;Hoeltgebaum H;Souza WM;Rocha EC;de Souza LM;de Pinho MC;Araujo LJT;Malta FSV;de Lima AB;Silva JDP;Zauli DAG;Ferreira ACS;Schnekenberg RP;Laydon DJ;Walker PGT;Schlüter HM;Dos Santos ALP;Vidal MS;Del Caro VS;Filho RMF;Dos Santos HM;Aguiar RS;Proença-Modena JL;Nelson B;Hay JA;Monod M;Miscouridou X;Coupland H;Sonabend R;Vollmer M;Gandy A;Prete CA Jr;Nascimento VH;Suchard MA;Bowden TA;Pond SLK;Wu CH;Ratmann O;Ferguson NM;Dye C;Loman NJ;Lemey P;Rambaut A;Fraiji NA;Carvalho MDPSS;Pybus OG;Flaxman S;Bhatt S;Sabino EC
通讯作者:
Sabino EC